PE20191476A1 - Nueva formulacion estable de anticuerpos anti-fxia - Google Patents
Nueva formulacion estable de anticuerpos anti-fxiaInfo
- Publication number
- PE20191476A1 PE20191476A1 PE2019001433A PE2019001433A PE20191476A1 PE 20191476 A1 PE20191476 A1 PE 20191476A1 PE 2019001433 A PE2019001433 A PE 2019001433A PE 2019001433 A PE2019001433 A PE 2019001433A PE 20191476 A1 PE20191476 A1 PE 20191476A1
- Authority
- PE
- Peru
- Prior art keywords
- stable formulation
- new stable
- fxia antibodies
- fxia
- formulation
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- 239000004471 Glycine Substances 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000009424 thromboembolic effect Effects 0.000 abstract 1
- 230000001732 thrombotic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Peptides Or Proteins (AREA)
Abstract
Referida a una formulacion farmaceutica liquida que comprende un anticuerpo anti-FXIA BAY1213790 en una concentracion de 10-40 mg/ml, histidina 5-10mM y glicina 130-200 mM, donde dicha formulacion tiene un pH de 5,7-6,3. La presente invencion es util en la terapia y la profilaxis de trastornos tromboticos o tromboembolicos
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17152108 | 2017-01-19 | ||
| PCT/EP2018/050951 WO2018134184A1 (en) | 2017-01-19 | 2018-01-16 | Novel stable formulation for fxia antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191476A1 true PE20191476A1 (es) | 2019-10-16 |
Family
ID=57914707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019001433A PE20191476A1 (es) | 2017-01-19 | 2018-01-16 | Nueva formulacion estable de anticuerpos anti-fxia |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20190367636A1 (es) |
| EP (1) | EP3570882B1 (es) |
| JP (1) | JP7072577B2 (es) |
| KR (1) | KR20190105588A (es) |
| CN (1) | CN110234353B (es) |
| AR (1) | AR110762A1 (es) |
| AU (1) | AU2018209118A1 (es) |
| BR (1) | BR112019014785A2 (es) |
| CA (1) | CA3050172A1 (es) |
| CY (1) | CY1124922T1 (es) |
| DK (1) | DK3570882T3 (es) |
| ES (1) | ES2904474T3 (es) |
| HR (1) | HRP20220011T1 (es) |
| HU (1) | HUE056858T2 (es) |
| IL (1) | IL267917B2 (es) |
| LT (1) | LT3570882T (es) |
| MX (1) | MX2019008544A (es) |
| PE (1) | PE20191476A1 (es) |
| PL (1) | PL3570882T3 (es) |
| PT (1) | PT3570882T (es) |
| RS (1) | RS62780B1 (es) |
| SG (1) | SG11201906557UA (es) |
| SI (1) | SI3570882T1 (es) |
| TW (1) | TWI753087B (es) |
| WO (1) | WO2018134184A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200312A1 (ar) | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
| TW201802121A (zh) | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
| CA3048156A1 (en) | 2016-12-23 | 2018-06-28 | Novartis Ag | Factor xi antibodies and methods of use |
| CN113474360B (zh) | 2019-02-18 | 2025-01-07 | 伊莱利利公司 | 治疗性抗体制剂 |
| IL293367A (en) * | 2019-12-20 | 2022-07-01 | Anthos Therapeutics Inc | Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies |
| WO2021198328A1 (en) * | 2020-04-03 | 2021-10-07 | Bayer Aktiengesellschaft | Pharmaceutical formulations polyethylene glycol-based prodrugs of adrenomedullin and use |
| AU2021302199A1 (en) | 2020-07-03 | 2023-02-23 | Suzhou Alphamab Co., Ltd. | Coagulation factor XI (FXI) binding protein |
| US20240383968A1 (en) * | 2020-12-11 | 2024-11-21 | Boehringer Ingelheim International Gmbh | Formulation for multi-purpose application |
| JP2025502861A (ja) * | 2022-01-05 | 2025-01-28 | 上▲海▼▲邁▼晋生物医▲薬▼科技有限公司 | 抗ＦＸＩ／ＦＸＩａ抗体を含む医薬組成物及びその使用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8632778B2 (en) * | 2000-08-11 | 2014-01-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized anti-interleukin-6 antibody-containing preparations |
| WO2004055164A2 (en) * | 2002-12-13 | 2004-07-01 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| PL2331090T3 (pl) * | 2008-09-19 | 2018-05-30 | Pfizer Inc. | Stabilny ciekły preparat przeciwciała |
| ES2719496T3 (es) * | 2008-11-12 | 2019-07-10 | Medimmune Llc | Formulación de anticuerpo |
| EP2847228B1 (en) | 2012-05-10 | 2018-07-25 | Bayer Pharma Aktiengesellschaft | Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof |
| DK3060256T3 (da) * | 2013-10-25 | 2019-07-29 | Bayer Pharma AG | Hidtil ukendt stabil formulering |
-
2018
- 2018-01-16 ES ES18702623T patent/ES2904474T3/es active Active
- 2018-01-16 DK DK18702623.2T patent/DK3570882T3/da active
- 2018-01-16 MX MX2019008544A patent/MX2019008544A/es unknown
- 2018-01-16 LT LTEPPCT/EP2018/050951T patent/LT3570882T/lt unknown
- 2018-01-16 EP EP18702623.2A patent/EP3570882B1/en active Active
- 2018-01-16 US US16/478,029 patent/US20190367636A1/en not_active Abandoned
- 2018-01-16 PL PL18702623T patent/PL3570882T3/pl unknown
- 2018-01-16 HR HRP20220011TT patent/HRP20220011T1/hr unknown
- 2018-01-16 HU HUE18702623A patent/HUE056858T2/hu unknown
- 2018-01-16 CA CA3050172A patent/CA3050172A1/en active Pending
- 2018-01-16 RS RS20220004A patent/RS62780B1/sr unknown
- 2018-01-16 SG SG11201906557UA patent/SG11201906557UA/en unknown
- 2018-01-16 WO PCT/EP2018/050951 patent/WO2018134184A1/en unknown
- 2018-01-16 PE PE2019001433A patent/PE20191476A1/es unknown
- 2018-01-16 IL IL267917A patent/IL267917B2/en unknown
- 2018-01-16 CN CN201880007721.1A patent/CN110234353B/zh active Active
- 2018-01-16 SI SI201830483T patent/SI3570882T1/sl unknown
- 2018-01-16 PT PT187026232T patent/PT3570882T/pt unknown
- 2018-01-16 BR BR112019014785-3A patent/BR112019014785A2/pt not_active Application Discontinuation
- 2018-01-16 AU AU2018209118A patent/AU2018209118A1/en active Pending
- 2018-01-16 JP JP2019538638A patent/JP7072577B2/ja active Active
- 2018-01-16 KR KR1020197020744A patent/KR20190105588A/ko active Pending
- 2018-01-17 TW TW107101631A patent/TWI753087B/zh active
- 2018-01-19 AR ARP180100130A patent/AR110762A1/es not_active Application Discontinuation
-
2022
- 2022-01-05 CY CY20221100009T patent/CY1124922T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3050172A1 (en) | 2018-07-26 |
| CN110234353A (zh) | 2019-09-13 |
| RU2019125947A3 (es) | 2021-05-25 |
| PT3570882T (pt) | 2022-01-11 |
| IL267917B2 (en) | 2023-10-01 |
| DK3570882T3 (da) | 2022-01-10 |
| EP3570882A1 (en) | 2019-11-27 |
| BR112019014785A2 (pt) | 2020-05-12 |
| RS62780B1 (sr) | 2022-01-31 |
| AR110762A1 (es) | 2019-05-02 |
| JP7072577B2 (ja) | 2022-05-20 |
| MX2019008544A (es) | 2019-10-07 |
| TW201831170A (zh) | 2018-09-01 |
| HUE056858T2 (hu) | 2022-03-28 |
| JP2020506175A (ja) | 2020-02-27 |
| KR20190105588A (ko) | 2019-09-17 |
| AU2018209118A1 (en) | 2019-07-11 |
| CY1124922T1 (el) | 2023-01-05 |
| ES2904474T3 (es) | 2022-04-05 |
| SG11201906557UA (en) | 2019-08-27 |
| SI3570882T1 (sl) | 2022-01-31 |
| EP3570882B1 (en) | 2021-11-17 |
| TWI753087B (zh) | 2022-01-21 |
| HRP20220011T1 (hr) | 2022-04-01 |
| US20190367636A1 (en) | 2019-12-05 |
| PL3570882T3 (pl) | 2022-02-07 |
| CN110234353B (zh) | 2023-07-04 |
| RU2019125947A (ru) | 2021-02-19 |
| IL267917B1 (en) | 2023-06-01 |
| WO2018134184A1 (en) | 2018-07-26 |
| LT3570882T (lt) | 2021-12-10 |
| IL267917A (en) | 2019-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191476A1 (es) | Nueva formulacion estable de anticuerpos anti-fxia | |
| AR130402A2 (es) | Formulaciones de anticuerpos anti-pdl1 | |
| CO2019009034A2 (es) | Formulación de anticuerpo monoclonal anti-vrs referencia cruzada a solicitudes relacionadas | |
| CY1126062T1 (el) | Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1 | |
| CL2018003022A1 (es) | Preparaciones que contienen anticuerpos. | |
| CY1123256T1 (el) | Συζευγματα αντισωματος enanti-cmet δραστικης ουσιας και μεθοδοι για τη χρηση αυτων | |
| MX2019010282A (es) | Formulacion de anticuerpos monoclonales. | |
| CL2020002012A1 (es) | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. (divisional solicitud 201903032) | |
| BR112017003419A2 (pt) | formulação de anticorpo anti-il-4r-alfa estável | |
| PE20190469A1 (es) | Formulaciones, kits y metodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados | |
| NZ743964A (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| BR112015024553A2 (pt) | anticorpo multiespecífico, anticorpo isolado, ácido nucleico isolado, célula hospedeira, método de produção de anticorpo, imunoconjugado, formulação farmacêutica, uso de anticorpo e método de tratamento de indivíduos com distúrbio | |
| PE20181790A1 (es) | Metodos para tratar o prevenir trastornos relacionados con el colesterol | |
| MX2022001146A (es) | Formulaciones de anticuerpos anti-pvrig y sus usos. | |
| EA201991464A1 (ru) | АНТИТЕЛО К α-СИНУКЛЕИНУ И ЕГО ПРИМЕНЕНИЕ | |
| JOP20190189A1 (ar) | تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t | |
| MX387451B (es) | Formulacion liquida que comprende un compuesto neutralizante de gm-csf. | |
| PE20191743A1 (es) | Anticuerpos biespecificos anti-pd-l1-anti-tim3 | |
| MX2023005896A (es) | Variantes de anticuerpos bovinos. | |
| EA202090944A1 (ru) | Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его | |
| MX2015009819A (es) | Anticuerpo humano especifico a metapneumovirus humano, o fragmento de union al antigeno del mismo. | |
| CO2021008755A2 (es) | Anticuerpo que se une a vegf y a il-1beta y métodos de utilización | |
| EA201991283A9 (ru) | Фармацевтическая композиция для предотвращения опиоидной зависимости | |
| MX2019007608A (es) | Composicion liquida de fibrinogeno humano. | |
| EA201891895A1 (ru) | ИНГИБИТОРЫ ВЗАИМОДЕЙСТВИЙ β-АРРЕСТИНА С РЕЦЕПТОРОМ НЕЙРОКИНИНА 1 ДЛЯ ЛЕЧЕНИЯ БОЛИ |